The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma-Reference-Cited by-同舟云学术

The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma

Published:2009-02 Issue:3 Volume:315 Page:485-497
ISSN:0014-4827
Container-title:Experimental Cell Research
language:en
Short-container-title:Experimental Cell Research

Author:

Baumann Philipp,Mandl-Weber Sonja,Oduncu Fuat,Schmidmaier Ralf

Publisher

Elsevier BV

Subject

Cell Biology

Reference38 articles.

1. Cancer statistics;Landis;CA Cancer J. Clin.,1999

2. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials;Gregory;J. Clin. Oncol.,1992

3. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials;J. Clin. Oncol.,1998

4. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma;Richardson;N. Engl. J. Med.,2005

5. Antitumor activity of thalidomide in refractory multiple myeloma;Singhal;N. Engl. J. Med.,1999

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification and panoramic analysis of drug response-related genes in triple negative breast cancer using as an example NVP-BEZ235;Scientific Reports;2023-04-12

2. Multiple myeloma metabolism – a treasure trove of therapeutic targets?;Frontiers in Immunology;2022-08-22

3. Involvement of the NF‐κB and PI3K /Akt/ mTOR pathways in cell death triggered by stypoldione, an o‐quinone isolated from the brown algae Stypopodium zonale;Environmental Toxicology;2022-02-07

Nanotechnology-Based Targeting of mTOR Signaling in Cancer

;International Journal of Nanomedicine;2020-08

5. A dual PI3 kinase/mTOR inhibitor BEZ235 reverses doxorubicin resistance in ABCB1 overexpressing ovarian and pancreatic cancer cell lines;Biochimica et Biophysica Acta (BBA) - General Subjects;2020-06